Incredibly Popular Peptide Regrew 'Irreplaceable' Cartilage
Dr. Brad Stanfield — Incredibly Popular Peptide Regrew 'Irreplaceable' Cartilage
Channel: Dr Brad Stanfield · Our label: Physician educator — skeptical, evidence-first voice · Source: youtube.com/watch?v=JM1he4pHzpw
What this video covers
In the early 1990s, an endocrinologist named John Eng walked into his lab at a VA hospital in Bronx with a vial of dried Gila monster venom. He’d ordered it from a mail-order catalog from a serpentarium in Utah. His colleagues thought he was just wasting his time. The idea that a poisonous desert lizard could teach us anything about human medicine seems, just to put it politely, unlikely.
Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.
Key points, in the speaker’s own framing
- 9 years after that, in April 2005, the FDA approved Byetta, the first GLP-1 medication ever made, and it was derived from the Gila monster venom.
- But then came semaglutide or Ozempic, and that one was approved in 2017 once a week, and each generation became more potent and longer-lasting.
- So, the FDA approved semaglutide specifically for obesity in 2021.
- The SELECT trial, which was a massive randomized clinical trial, showed that semaglutide reduced major cardiovascular events by 20% in people with obesity who did not have diabetes.
- A large VA study found that patients on GLP-1 medications had significantly lower rates of substance abuse.
- So, the FLOW trial showed that semaglutide reduced risks and slowed disease progression.
Read next
- GLP-1 class — more videos
- Semaglutide — more videos
- Liraglutide — more videos
- All videos from this channel
Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.